// App-Quantinova.ai

1337 : Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis

Researchers

Presenter

  • Pavel Belomestnov

Principal Investigators

  • Jennifer Hamilton

  • A. Thomas DiCioccio

  • Martine Jasson

  • Allen R. Radin

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Regeneron Pharmaceut

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • High sensitivity C-reactive protein

  • Interleukin 6

  • Serum amyloid A

Drug/Treatment

  • Methotrexate

  • Sarilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved